Skip to main content

Table 5 Rituximab maintenance therapy for indolent lymphoma

From: Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

Study Disease, treatment Induction treatment Maintenance schedule Trial design No. of patients Outcomes Study arm Control arm P value
Hainsworth et al. [31] FL/SLL R weekly (4 times) 4 weeks R q 6 months × 4 times Randomized phase II 114 PFS (median) 31.3 months 7.4 months 0.007
Williams et al. [30] SLL/MZL R weekly (4 times) R q 3 months till PD Phase III 128 TTP (median) 4.8 years 1.4 years 0.012
Taverna et al. [37] FL (including relapse) R weekly (4 times) R q 2 months for 8 month vs 5 years Phase III 165 EFS 3.4 years (8 months) 5.3 year (5 years) 0.14
Salles et al. [28] FL R–CVP/R–CHOP/R-FCM R q 2 months for 2 years Phase III 1019 PFS (3 years) 74.9% 57.6% < 0.0001
Rummel et al. [35] MZL R–B + 2R R q 2 months for 2 years Randomized phase II 104 PFS (median) Not reached 92.2 months 0.008
Oh (present study) MZL R–CVP R q 2 months for 2 years Phase II 45 PFS (3 years) 81%
  1. PFS progression-free survival, EFS event-free survival, TTP time to progression, PD progression of disease, MZL marginal zone B-cell lymphoma, FL follicular lymphoma, SLL small lymphocytic lymphoma, R rituximab, MALT mucosa-associated lymphoid tissue, R–CVP rituximab-cyclophosphamide, vincristine, and prednisolone, R–CHOP rituximab–cyclophosphamide, doxorubicin, vincristine, and prednisolone, R–FCM rituximab–fludarabine, cyclophosphamide, and mitoxantrone, R–Cb rituximab–chlorambucil, R–B rituximab–bendamustine